Just four years after receiving FDA clearance for Cologuard, Exact Sciences Corp.’s non-invasive, at-home screening test for colorectal cancer has been used by more than 1 million qualified adults to screen for the nation’s No. 2 cancer killer, according to a company release.
In 2018, Exact Sciences anticipates revenue of $420-$430 million and a completed Cologuard test volume of 900,000–920,000 tests.
